We are live on ! Find out more
TSVT

2seventy bio

Delisted

TSVT was delisted on the 13th of May, 2025.

139 hedge funds and large institutions have $234M invested in 2seventy bio in 2025 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 20 increasing their positions, 42 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

422% more call options, than puts

Call options by funds: $710K | Put options by funds: $136K

114% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 21

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

74% more capital invested

Capital invested by funds: $135M → $234M (+$99.4M)

20% more funds holding

Funds holding: 116139 (+23)

52% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 42

Holders
139
Holders Change
+23
Holders Change %
+19.83%
% of All Funds
1.86%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
45
Increased
20
Reduced
42
Closed
21
Calls
$710K
Puts
$136K
Net Calls
+$574K
Net Calls Change
+$528K

TSVT Hedge Fund Activity: Q1 2025 in Review

139 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in 2seventy bio (TSVT) for Q1 2025, worth a combined $234M — up 74% from $135M a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new TSVT positions and 21 closed out — a net gain of 24 holders — while 20 added to existing stakes and 42 trimmed.

The largest buyer was Beryl Capital Management, opening a new position worth an estimated $13.5M. The largest seller was Kynam Capital Management, exiting entirely with an estimated $17.5M sold.

  • 139 institutional investors held 2seventy bio (TSVT) as of Q1 2025, up from 116 in Q4 2024.
  • Funds reported $234M of 2seventy bio stock for Q1 2025, up 74% quarter-over-quarter.
  • 45 funds opened new 2seventy bio positions in Q1 2025 and 21 closed out, a net change of +24 holders.
  • The largest 2seventy bio buyer in Q1 2025 was Beryl Capital Management, an estimated $13.5M added.
  • The largest 2seventy bio seller in Q1 2025 was Kynam Capital Management, an estimated $17.5M sold.

Based on aggregated 13F filings for Q1 2025.